Research and Markets: Biomarker Research in Parkinson's Disease

DUBLIN -- Research and Markets
has announced the addition of Future Medicine Ltd's new report "Biomarker Research in Parkinson's Disease" to their offering.

The concept of 'personalized medicine' has reached the forefront of neurodegenerative diseases. There is a need for objective markers of Parkinson's disease that can indicate the biological processes underlying each variant of the disease. In this way, variant-specific trial enrollment is promoted and, in the future, successful treatment plans can be devised.

The October issue of Biomarkers in Medicine covers several aspects of Parkinson's disease biomarker research, including relevance and classification, functional analysis of neural tissue, interrogation of biological fluids, and assessment of genetic traits. In addition, the issue features unique reports from the perspectives of funding agencies and venture capitalists.

Key Topics Covered:

FOREWARD

Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials Michael G Schlossmacher, Brit Mollenhauer

REVIEWS

Imaging dopamine transporters in Parkinson's disease
Olfaction as a biomarker in Parkinson's disease
Problems associated with fluid biomarkers for Parkinson's disease
Quantification of a-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies
Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis
Autosomal recessive mutations in the development of Parkinson's disease

SPECIAL REPORTS

Biomarkers in Parkinson's disease: a funder's perspective
Biomarkers in Parkinson's disease: a venture capitalist's perspective

For more information and to view a sample visit http://www.researchandmarkets.com/research/97c6cc/biomarker_research

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.